(1R,2S,7S,10R,11S,13R,15S,16R,19R)-7-[(2R,4R,5S,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,15,19-trimethyl-14-oxapentacyclo[11.5.1.02,11.05,10.016,19]nonadec-4-ene-12,18-dione

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1R,2S,7S,10R,11S,13R,15S,16R,19R)-7-[(2R,4R,5S,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,15,19-trimethyl-14-oxapentacyclo[11.5.1.02,11.05,10.016,19]nonadec-4-ene-12,18-dione
• 化学式: C₂₈H₄₀O₇
• 分子量: 488.6
• InChiKey: WOLJVUSLKTUJMB-IRXHHZSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  35
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  91.3
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• MultiLigand Agent for Drug Delivery
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20170028074A1

  公开（公告）日：2017-02-02

  Described herein is a compound having the structure of formula I, II, or III, wherein R comprises a double stranded RNA molecule, and L 1 , L 2 , and L 3 independently for each occurrence comprise a ligand selected from the group consisting of a carbohydrate, a cholesteryl, or a peptide; a pharmaceutically accepted salt or pharmaceutical composition thereof; and a method of making the compound.

  本文描述了一种具有化学式I、II或III结构的化合物，其中R包括一种双链RNA分子，而每次出现的L1、L2和L3独立地包括从碳水化合物、胆固醇或肽组成的配体中选择的配体；以及该化合物的药学接受的盐或药物组合物；以及制备该化合物的方法。
• [EN] 18F-SACCHARIDE-FOLATES<br/>[FR] 18F-SACCHARIDE-FOLATES
  申请人：MERCK & CIE

  公开号：WO2013026842A1

  公开（公告）日：2013-02-28

  The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18Fisotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as acyclic mono-or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folateor derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

  本发明涉及新的18F-叶酸放射性药物，其中18F同位素通过一个假体基团连接，更具体地通过一个具有糖苷基团的假体基团连接，例如非环式单糖或寡糖，最好基于吡喃糖苷或呋喃糖苷，它与叶酸或其衍生物的谷氨酸部分共价连接，以及它们的制备方法，以及它们在癌症、炎症和自身免疫疾病的诊断和监测以及治疗中的应用。
• 18F-SACCHARIDE-FOLATES
  申请人：Schibli Roger

  公开号：US20140193337A1

  公开（公告）日：2014-07-10

  The present invention is directed towards new 18 F-folate radiopharmaceuticals, wherein the 18 F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

  本发明涉及新的18F-叶酸类放射性药物，其中18F同位素通过一个假体基团连接，更具体地说是通过一个带有糖苷基团的假体基团连接，比如基于吡喃苷或呋喃苷的环状单糖或寡糖，该基团共价连接到叶酸或其衍生物的谷氨酸部分，以及它们的制备方法，以及在癌症、炎症性和自身免疫性疾病的诊断和监测以及治疗中的使用。
• C-8 HALOGENATED MACROLIDES
  申请人：KIM IN JONG

  公开号：US20090209547A1

  公开（公告）日：2009-08-20

  The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物（I）或其药用可接受的盐、酯或前药：该化合物具有抗菌性能。本发明还涉及包括上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。